Abstract | BACKGROUND: METHOD: In this 8-week, 2-site (S1, S2), open-label trial, 30 adults (16 at S1 and 14 at S2) with a DSM-IV diagnosis of OCD, SRI-resistant, received augmentation with quetiapine, with the dose doubled every 2 weeks from 25 mg to 200 mg/day. Primary outcome was measured with the Yale-Brown Obsessive Compulsive Scale (YBOCS). A response was defined as a > or = 25% decrease from the baseline YBOCS score. RESULTS: Significant differences between the sites in patient characteristics (7/14 at S2 were hoarders, i.e., more treatment resistant, vs. 1/16 at S1; p = .01) and in quetiapine treatment (mean +/- SD dose of 116 +/- 72 mg/day at S2 vs. 169 +/- 57 mg/day at S1; p = .039) necessitated separate analysis of results. At S1, the mean +/- SD YBOCS score fell significantly from 27.7 +/- 7.0 to 23.3 +/- 8.4 (t = 2.96, df = 15, p = .01), and the responder rate was 31% (5/16). At S2, the mean YBOCS score did not decrease significantly, and the responder rate was 14% (2/14). Most adverse medication events were mild or moderate. Two subjects (13%) at S1 and 3 (21%) at S2 withdrew due to adverse events. CONCLUSION: The results at S1 resemble those reported with other atypical antipsychotics and suggest that quetiapine augmentation may benefit treatment-resistant OCD. The poorer results at S2 may reflect the large proportion of hoarders or the less intense treatment. Longer, higher dose, large, double-blind, placebo-controlled comparison trials of atypical antipsychotics are needed.
|
Authors | Ann M Bogan, Lorrin M Koran, Helen W Chuong, Tanya Vapnik, Alexander Bystritsky |
Journal | The Journal of clinical psychiatry
(J Clin Psychiatry)
Vol. 66
Issue 1
Pg. 73-9
(Jan 2005)
ISSN: 0160-6689 [Print] United States |
PMID | 15669891
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antipsychotic Agents
- Dibenzothiazepines
- Serotonin Uptake Inhibitors
- Quetiapine Fumarate
|
Topics |
- Antipsychotic Agents
(therapeutic use)
- Anxiety Disorders
(epidemiology)
- Comorbidity
- Depressive Disorder, Major
(epidemiology)
- Dibenzothiazepines
(therapeutic use)
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Drug Resistance
- Drug Therapy, Combination
- Humans
- Obsessive-Compulsive Disorder
(drug therapy, epidemiology, psychology)
- Psychiatric Status Rating Scales
- Quetiapine Fumarate
- Selective Serotonin Reuptake Inhibitors
(therapeutic use)
- Treatment Outcome
|